Attachment_13_-_FDA_Investigations_Operations_Manual _Chapter_4._Sample_Schedules.pdf

INVESTIGATIONS OPERATIONS MANUAL 2015 CHAPTER 4

CHAPTER 4 - SAMPLING

CONTENTS

SUBCHAPTER 4.1 - GENERAL

4.1.1 - AUTHORITY

4.1.1.1 - Examinations and Investigations

4.1.1.2 - Notice of Inspection

4.1.1.3 - Receipt for Sample

4.1.1.4 - Report of Analysis

4.1.2 - VALID SAMPLE

4.1.3 - RESPONSIBILITY

4.1.4 - OFFICIAL SAMPLES (21 CFR 2.10)

4.1.4.1 - Definition - Official Sample

4.1.4.2 - Documentary Samples

4.1.4.3 - In-Transit Samples

4.1.4.4 - 301(k) Samples

4.1.4.5 - Induced Sample

4.1.4.6 - Undercover Buy

4.1.4.7 - Post Seizure (P.S.) Sample

4.1.4.8 - Domestic Import Sample

4.1.4.9 - Import Sample

4.1.4.10 - Additional Sample

4.1.4.11 – Reconditioning Sample

4.1.4.12 - Audit/Certification Sample

4.1.4.13 - Mail Entry Sample

4.1.5 - FOOD STANDARDS SAMPLE

4.1.6 - INVESTIGATIONAL SAMPLES

4.1.6.1 - Non-Regulatory Sample

SUBCHAPTER 4.2 - DEALER RELATIONS

4.2.1 - DEALER DEFINITION AND GOOD WILL

4.2.2 - DEALER OBJECTION TO SAMPLING

PROCEDURE

4.2.3 - REFUSAL TO PERMIT SAMPLING

4.2.3.1 - Limiting or Preventing Collection of Samples of a Drug

4.2.4 - NOTICE OF INSPECTION

4.2.4.1 - Dealer Responsible for Condition of Lot

4.2.4.2 - Refusals

4.2.4.3 - Carrier In-Transit Sampling

4.2.4.4 - Dealer Requests Notice of Inspection

4.2.5 - RECEIPT FOR SAMPLES

4.2.5.1 - Carriers/In-Transit Lots

4.2.5.2 - Dealer Requests Receipt

4.2.5.3 - Narcotic and Controlled Rx Drugs

4.2.5.4 - Prescription Drugs (Non-Controlled)

4.2.5.5 - Preparation of FDA 484

4.2.5.6 - Routing of FDA 484

4.2.6 - DEALER IDENTIFICATION OF LOT AND

RECORDS

4.2.6.1 - Private Individuals

4.2.6.2 - Seriously Ill Individuals

4.2.7 - SAMPLING FROM GOVERNMENT AGENCIES 119

4.2.8 - PAYMENT FOR SAMPLES

4.2.8.1 - Post Seizure (P.S.) and Reconditioning Samples under Court Order

4.2.8.2 - Determining Sample Cost

4.2.8.3 - Method of Payment

4.2.8.3.1 - Costs Billed To District

4.2.8.3.2 - Cash Payment

4.2.8.4 - Sampling - Labor Charges

4.2.9 - VOLUNTARY EMBARGO

4.2.9.1 - Perishable Goods

4.2.9.2 - Obtaining a Voluntary Embargo

SUBCHAPTER 4.3 - COLLECTION TECHNIQUE

4.3.1 - RESPONSIBILITY

4.3.2 - LOT RESTORATION & IDENTIFICATION

4.3.2.1 - Restoring Lot(s) Sampled

4.3.2.2 - Identifying Lot(s) Sampled

4.3.3 - SAMPLE SIZE

4.3.3.1 - Medical Device Samples

4.3.3.2 - 702(b) Requirement

4.3.3.3 - Collecting the 702(b) Portion

4.3.4 - IN-TRANSIT SAMPLES

4.3.4.1- Examination without a Warrant

4.3.4.2 - Examination with a Warrant

4.3.4.3 - Resealing Conveyances

4.3.5 - SPECIAL SAMPLING SITUATIONS

4.3.5.1 - Complaints, Counterfeiting / Tampering, Foodborne Disease, Injury Illness

4.3.5.2 - Recalls

4.3.5.3 - Natural Disasters

4.3.5.4 - Induced Samples

4.3.5.5 - Undercover Buy

4.3.6 - ASEPTIC SAMPLE

4.3.6.1 - General Procedures

4.3.6.1.1 - Sterilized Equipment

4.3.6.1.2 - CAUTIONS

4.3.6.1.3 - Opening Sterile Sampling Containers

4.3.6.1.4 - Dusty Areas

4.3.6.2 - Sampling Dried Powders

4.3.6.2.1 - Bag And Poly-Liner Stitched Together Across Top Seam

4.3.6.2.2 - Bag Stitched Across Top And Poly-Liner Twist- Closed And Sealed With "Twist" Device - Wire, Plastic, Etc

4.3.6.2.3 - Bags With Filling Spouts

4.3.6.3 - Collecting Water Samples

4.3.6.4 - Sample Handling

4.3.6.5 – Closed Controls

4.3.7 - ADULTERATION VIOLATIONS

4.3.7.1 - Field Examination

4.3.7.2 - Random Sampling

4.3.7.3 - Selective Sampling

4.3.7.4 - Sample Criteria

4.3.7.4.1 - General

4.3.7.4.2 - Rodent Contamination

4.3.7.4.2.1 - Examination and Documentation of Rodent Contamination

4.3.7.4.2.2 - Collecting Exhibits or Subsamples

4.3.7.4.2.3 - Summary of Sample for Rodent Evidence .128

4.3.7.4.3 - Insect Contamination

4.3.7.4.3.1 - Examination and Documentation of Insect Contamination

4.3.7.4.3.2 - Collecting Exhibits or Subsamples

4.3.7.4.3.3 - Summary of Sample for Insect Evidence ...129

4.3.7.4.4 - Bird Contamination

4.3.7.4.4.1 - Examination and Documentation of Bird Contamination

4.3.7.4.4.2 - Collecting Exhibits and Subsamples

4.3.7.4.4.3 - Summary of Sample for Bird Evidence

4.3.7.4.5 - Chemical Contamination

4.3.7.4.6 - Mold Contamination

4.3.7.5 - Abnormal Containers

4.3.7.6 - Microbiological Samples

4.3.7.6.1 – Collection Of Samples For Molds

4.3.7.7 – Collection of Environmental and Product Samples for Food Susceptible to Contamination with Pathogenic Microorganisms

4.3.7.7.1 - Environmental Sampling

CHAPTER 4 INVESTIGATIONS OPERATIONS MANUAL 2015

4.3.7.7.2 - Environmental Sampling Equipment And Instructions For Large And Small Area Environmental Surface Sampling

4.3.7.7.3 – In-Line Sampling/Factory Food Sample

4.3.7.7.4 - Finished Product Sampling

4.3.7.7.5 - Reporting Environmental Sampling Results On The FDA 483

4.3.7.8 - Samples for Viral Analysis

4.3.8 - ECONOMIC VIOLATIONS

4.3.8.1 - Net Weight

4.3.8.1.1 - Tare Determination

4.3.8.1.2 - Field Examination

4.3.8.1.3 - Field Weight Sheet

4.3.8.2 - Volume Determination

4.3.8.2.1 - Free Flowing Liquids

4.3.8.2.2 - Viscous Liquids

4.3.8.3 - Labeling

4.3.9 - ORGANOLEPTIC EXAMINATIONS

4.3.9.1 - Whole-Bag Screening

SUBCHAPTER 4.4 - DOCUMENTATION & CR

4.4.1 - AUTHORITY

4.4.2 - OBJECTIVE

4.4.3 - POLICY

4.4.3.1 - Collection Records

4.4.4 - RESPONSIBILITY

4.4.5 - SAMPLE RECORDS IDENTIFICATION

4.4.6 - EVIDENCE REQUIRED

4.4.6.1 - Seizure

4.4.6.2 - Injunction or Criminal Prosecution

4.4.6.2.1 - Introduction Into Interstate Commerce

4.4.6.2.2 - Adulteration Or Misbranding In Interstate Commerce

4.4.6.2.3 - Receipt In Interstate Commerce

4.4.6.2.4 - Manufacture Within A Territory

4.4.6.2.5 - False Guaranty

4.4.6.2.6 - Dealer Violation

4.4.6.3 - Complaint or Injury Samples

4.4.7 - DOCUMENTING INTERSTATE SHIPMENTS ... 140

4.4.7.1 - Sales Records

4.4.7.2 - Transportation Records for Common Carrier Shipments

4.4.7.2.1 - Refusal To Permit Access To Records In Possession Of Common Carriers

4.4.7.2.2 - Written Request For Records

4.4.7.2.3 - Bill Of Lading

4.4.7.2.4 - Freight Bill

4.4.7.2.5 - Waybill

4.4.7.3 - Mail or Parcel Service Shipments

4.4.7.4 - Shipment by Privately-Owned Conveyance

4.4.7.5 - In-Transit Sampling Affidavit

4.4.8 - AFFIDAVITS

4.4.8.1 - General Considerations for all Affidavits

4.4.8.2 - Refusal to Sign the Affidavit

4.4.8.3 - Confidential Informants

4.4.8.4 - Affidavit (Dealer/Warehouseman)

4.4.8.5 - Affidavit (FDA 463a)

4.4.8.6 - Affidavit (Jobber)

4.4.9 - LABELS AND LABELING

4.4.9.1 - Labels & Accompanying Labeling

4.4.9.2 - Bulk Shipments

4.4.9.3 - Unlabeled or Partially Labeled Lot

4.4.9.3.1 - Documentation

4.4.10 - REPORTING SAMPLE COLLECTIONS

4.4.10.1 - Flag

4.4.10.1.1 - 301(K) Sample

4.4.10.1.2 - Complaint Sample

4.4.10.1.3 - Dealer Voluntarily Holding

4.4.10.1.4 - Exhibit Sample

4.4.10.1.5 - Factory Food Sample

4.4.10.1.6 - Fumigated

4.4.10.1.7 - Inv. Samples Of Filth Exhibits

4.4.10.1.8 - Pesticide Sample

4.4.10.1.9 - Reconditioned

4.4.10.1.10 - Sampled In Transit

4.4.10.1.11 - Split Sample

4.4.10.1.12 - Survey Sample

4.4.10.1.13 - Under State Embargo

4.4.10.2 - Type Identification

4.4.10.2.1 - Additional (ADD)

4.4.10.2.2 - Audit/Certification

4.4.10.2.3 - Documentary (DOC)

4.4.10.2.4 - Domestic Import (DI)

4.4.10.2.5 - Food Standards (FS)

4.4.10.2.6 - Investigational (INV)

4.4.10.2.7 - Mail Entry

4.4.10.2.8 - Non-Regulatory

4.4.10.2.9 - Official

4.4.10.2.10 - Post Seizure (PS)

4.4.10.2.11 - Regulatory

4.4.10.3 - Preparation

4.4.10.3.1 - Accomplishment Hours

4.4.10.3.2 - Analytical Assignment

4.4.10.3.3 - Brand Name

4.4.10.3.4 - Carrier Name

4.4.10.3.5 - Collection Date

4.4.10.3.6 - Collection Method

4.4.10.3.7 - Collection Pacs

4.4.10.3.8 - Collection Reason

4.4.10.3.9 - Collection Remarks

4.4.10.3.10 - Collector

4.4.10.3.11 - Collector's Id On Package/Document

4.4.10.3.12 - Collector's Id On Seal

4.4.10.3.13 - Consumer Complaint Number

4.4.10.3.14 - Country Of Origin

4.4.10.3.15 - County

4.4.10.3.16 - Cr & Records Sent To

4.4.10.3.17 - CRX/DEA Schedule

4.4.10.3.18 - Dairy Permit Number

4.4.10.3.19 - Date Collected

4.4.10.3.20 - Date Shipped

4.4.10.3.21 - Documents Obtained

4.4.10.3.22 - Episode Number

4.4.10.3.23 - Estimated Value

4.4.10.3.24 - FEI Number

4.4.10.3.25 - Firm Name

4.4.10.3.26 - Firm Type

4.4.10.3.26.1 - Dealer

4.4.10.3.26.2 - Grower

4.4.10.3.26.3 - Harvester

4.4.10.3.26.4 - Ingredient Supplier

4.4.10.3.26.5 - Manufacturer

4.4.10.3.26.6 - Shipper

4.4.10.3.27 - FIS Sample Number

4.4.10.3.28 - Food Canning Establishment

4.4.10.3.29 - Hours

4.4.10.3.30 - How Prepared

4.4.10.3.31 - Lot Size

4.4.10.3.32 - Manufacturing Codes

4.4.10.3.33 - Method Of Collection

4.4.10.3.34 - National Drug Code

4.4.10.3.35 - Orig CR & Records To

4.4.10.3.36 - Payment Method

4.4.10.3.37 - Permit Number

4.4.10.3.38 - Product Code

4.4.10.3.39 - Product Description

4.4.10.3.40 - Product Label

4.4.10.3.41 - Product Name

4.4.10.3.42 - Reason For Collection

4.4.10.3.43 - Recall Number

4.4.10.3.44 - Receipt Issued

4.4.10.3.45 - Receipt Type

4.4.10.3.46 - Related Samples

4.4.10.3.47 - Resp. Firm Type

4.4.10.3.48 - Sample Basis

4.4.10.3.49 - Sample Class

4.4.10.3.50 - Sample Cost

4.4.10.3.51 - Sample Delivered Date

4.4.10.3.52 - Sample Delivered To

4.4.10.3.53 - Sample Description

4.4.10.3.54 - Sample Flags

4.4.10.3.55 - Sample Number

4.4.10.3.56 - Sample Origin

4.4.10.3.57 - Sample Sent To

4.4.10.3.58 - Sample Type

4.4.10.3.59 - Sampling District

4.4.10.3.60 - State

4.4.10.3.61 - Status

4.4.10.3.62 - Storage Requirements

4.4.10.3.63 - 702(b) Portion Collected

4.4.10.3.64 - 704(d) Sample

4.4.10.4 – Servicing Laboratory Table (SLT)

4.4.10.4.1 – Other Information

4.4.10.5 - Routing

SUBCHAPTER 4.5 - SAMPLING: PREPARATION,

HANDLING, SHIPPING

4.5.1 - OBJECTIVE

4.5.2 - IDENTIFYING MARKS

4.5.2.1 - Subsamples

4.5.2.2 - Borrowed Samples

4.5.2.3 - Identification Techniques

4.5.2.4 - Photographs

4.5.2.5 - Records - Accompanying Literature and Exhibits

4.5.3 - SAMPLE HANDLING

4.5.3.1 - Fumigation

4.5.3.1.1 - FUMIGATION SAFETY PRECAUTIONS

4.5.3.1.2 - Procedures For Fumigation

4.5.3.1.3 - Exceptions To Fumigation

4.5.3.1.4 - Preservation Liquids

4.5.3.2 - Labeling

4.5.3.3 - Samples for Pathological Examination

4.5.3.4 - Small Sample Items

4.5.3.5 - Frozen Samples

4.5.3.5.1 - Shipping Frozen Samples

4.5.3.5.2 - Control

4.5.3.6 - Refrigerated (Not Frozen) Samples

4.5.3.6.1 - Control

4.5.4 - OFFICIAL SEALS

4.5.4.1 - Preparation

4.5.4.2 - Application

4.5.4.3 - Sealing Method

4.5.4.4 - Protecting the Official Seal

4.5.4.5 - Broken Official Seals and "Temporary Seals" . 157

4.5.4.6 - Metal Seals

4.5.4.7 - Sealing Non-Sample Items

4.5.5 - SAMPLE SHIPMENT

4.5.5.1 - Sample Package Identification and FDA 525 .. 157

4.5.5.2 - Routing of Samples

4.5.5.3 - Samples to Administration Laboratories

4.5.5.3.1 - Split Samples

4.5.5.3.2 - National Center For Drug Analysis Or Headquarters' Division

4.5.5.3.3 - Center For Food Safety And Applied Nutrition(CFSAN)

4.5.5.3.4 - Center For Drug Evaluation And Research Division Of Pharmaceutical Analysis (DPA)

4.5.5.3.5 - Center For Biologics Evaluation And Research

(CBER)

4.5.5.3.6 - Center For Devices And Radiological Health

(CDRH)

4.5.5.3.7 - Center For Veterinary Medicine (CVM)

4.5.5.3.8 - Center For Tobacco Products (CTP)

4.5.5.4 - Sample Shipment to Outside Agencies

4.5.5.5 - Notifying Receiving Laboratories

4.5.5.6 - Method of Shipment

4.5.5.7 - Parcel Post

4.5.5.8 - Common Carrier

4.5.5.8.1 - Shipment

4.5.5.8.2 - Designated Carriers

4.5.5.8.3 - Government Bill Of Lading

4.5.5.8.4 - Commercial Bill Of Lading

4.5.5.8.5 - Address Labels

4.5.5.8.6 - Shipment Of Hazardous Or Toxic Items

4.5.5.8.7 - PRECAUTIONS

4.5.5.9 - Certified and First Class Mail

4.5.6 - Payment Of Shipping Charges

CHAPTER 4 EXHIBITS AND SAMPLE SCHEDULES...163

PRODUCT LABELING EXAMPLE

4-1 FACTS SAMPLE COLLECTION SCREEN

4-2 FACTS SAMPLE COLLECTION SCREEN

4-3 AFFIDAVIT (IN -TRANSIT) - FDA 1664b

4-4 CARRIER'S RECEIPT FOR SAMPLE - FDA 472

4-5 RECEIPT FOR SAMPLES - FDA 484

4-6 FIELD WEIGHT SHEET - FDA 485

4-7 AFFIDAVIT - "301(k) Sample" - FDA 463a

4-8 COPY OF INVOICE/SHIPPING RECORD - FD 1662

4-9 AFFIDAVIT(PARCEL POST) - FDA 463

4-10 AFFIDAVIT - FDA 463a 4-11 AFFIDAVIT - FDA 463a 4-12 AFFIDAVIT - (Dealer/Warehouseman) - FDA 1664 4-13 AFFIDAVIT - FDA 463a 4-14 AFFIDAVIT - (Jobber) - FDA 1664a

4-15 FACTS SAMPLE COLLECTION SCREEN

4-16 FACTS SAMPLE COLLECTION SCREEN

4-17 OFFICIAL SEAL - FDA 415a

4-18 DECLARATION FOR DANGEROUS GOODS

4-19 DRY ICE STICKER

4-20 ENVIRONMENTAL SAMPLING FOR THE

DETECTION OF LISTERIA MONOCYTOGENES

4-21 ENVIRONMENTAL SAMPLING FOR THE

DETECTION OF Salmonella

1-SALMONELLA SAMPLING PLAN

2-SAMPLING SCHEDULE FOR CANNED AND

ACIDIFIED FOODS

3-PESTICIDE SAMPLES

4-WHEAT CARLOAD SAMPLING

5-IMPORTED WHITEFISH SAMPLING SCHEDULE

6-AFLATOXIN SAMPLE SIZES

7-CANNED FRUIT - FILL OF CONTAINER - AUTHENTIC

PACK

8-IMPORTS - COFFEE, DATES AND DATE MATERIAL

9-SAMPLING SCHEDULE FOR COLOR CONTAINING

PRODUCTS & COLOR ADDITIVES

10-DRUG SAMPLING SCHEDULES

11-VETERINARY PRODUCTS, FEEDS, & BY-

PRODUCTS FOR ANIMAL FEEDS

12-MEDICATED ANIMAL FEEDS SAMPLING

13-SAMPLE SIZES WITH APPLICATION TO FOOD

PRODUCTS FOR ALLERGENS

SUBCHAPTER 4.1 - GENERAL

4.1.1 - AUTHORITY

4.1.1.1 - Examinations and Investigations Collecting samples is a critical part of FDA's regulatory activities. FD&C Act, Section 702(a) [21 U.S.C. 372 (a)] gives FDA authority to conduct investigations and collect samples. A Notice of Inspection is not always required for sample collections. If during a sample collection, you be-gin to conduct an inspection (examining storage condi-tions, reviewing records for compliance with laws and regulations, etc.), issue an FDA 482 and continue your activities. See IOM 5.1.1 and 5.2.2.

While inspections and investigations may precede sample collection, a sample must ultimately be obtained for a case to proceed, under the law. Proper sample collection is the keystone of effective enforcement action.

FD&C Act - See IOM section 2.2.1 for this information.

PHS Act - See IOM 2.2.3.7 for this information.

4.1.1.2 - Notice of Inspection

Samples are often collected during the course of an es-tablishment inspection or inspection of a vehicle. See IOM

5.1.1 and IOM 5.2.2.

1. Carriers - Issue an FDA 482 - Notice of Inspection to the driver or agent when it is necessary to inspect vehicles. See IOM 5.2.2.2.

2. Manufacturers, etc. – Issue an FDA 482 - Notice of Inspection when samples are collected from lots in possession of a manufacturer, processor, packer or repacker, whether or not regulatory action is intended toward the articles, the dealer, the manufacturer or the shipper.

4.1.1.3 - Receipt for Sample Section 704(c) of the FD&C Act [21 U.S.C. 374 (c)] re-quires issuing a receipt describing any samples obtained during the course of an inspection. The receipt is to be issued to the owner, operator, or agent in charge, upon completion of the inspection and prior to leaving the premises. See IOM 5.2.4 for special situations. See IOM

4.2.5.5 for instructions on completing the form.

4.1.1.4 - Report of Analysis Section 704(d) of the FD&C Act [21 U.S.C. 374 (d)] re-quires FDA furnish a report of analysis on any sample of food (including animal food and feed, medicated and non-medicated), collected during an inspection of an estab-lishment where such food is "*** manufactured, proc-essed, or packed ***," if the sample is examined for compliance with Section 402(a)(3) of the FD&C Act [21 U.S.C. 342 (a)(3)]. The servicing laboratory is responsible for furnishing the report of analysis. See FMD 147.

4.1.2 - VALID SAMPLE

A valid sample is the starting point and keystone for most administrative and legal actions. As evidence, the sample must support the government's charge there is a violation of the law. Also, it must conform to the rules on admissi-bility of evidence. A properly collected and prepared sam-ple provides:

1. A portion of the lot of goods for laboratory analysis and reserve, a 702(b) of the FD&C Act [21 U.S.C. 374 (b)] reserve portion if appropriate, and/or an exhibit dem-onstrating the violation represented by the lot.

2. A report of your observations of the lot.

3. Labels and labeling, or copies of such, which "accom-pany" the goods.

4. Documentary evidence of federal jurisdiction over the lot, information about individuals responsible for the violation, where the violation was committed, and similar data.

5. Signed statements from persons who may be called upon as witnesses, if there is a subsequent court ac-tion.

4.1.3 - RESPONSIBILITY

Collect every sample as if you will be required to testify in court about everything you did concerning each and every event surrounding the sample collection. Mistakes or defi-ciencies, however trivial they may seem, can fatally dam-age the government's case. Be objective, accurate, and thorough.

4.1.4 - OFFICIAL SAMPLES (21 CFR 2.10)

A sample of a food, drug, or cosmetic is an "Official Sam-ple" if records [see IOM 4.4.7] or other evidence obtained shows the lot from which the sample was collected was:

1. Introduced or delivered for introduction in interstate commerce, or

2. Was in or was received in interstate commerce, or

3. Was manufactured in a territory or the District of

Columbia.

A sample of a device, a counterfeit drug, or any object associated with drug counterfeiting, no matter where it is collected, is also an "Official Sample". The statute permits proceeding against these articles, when violative, at any time. See Sections 304(a)(2) of the FD&C Act [21 U.S.C.

334 (a)(2)].

Import Samples are Official Samples and require the same integrity as domestic Official Samples. They must be identified with sample number, collection date and col-lector's handwritten initials. Interstate documentation is not required; see CPG manual section 110.200 and 110.600.

Import Samples need not be sealed, unless District policy dictates, as long as the integrity of the sample is main-tained.

Normally, 702(b) of the FD&C Act [21 U.S.C. 374 (b)] por-tions (hereby referred to as either 702(b) portion or 702(b) reserve portion) are not collected for routine Import Sam-ples. However, in situations where a dispute arises or a potential for regulatory action exists, the 702(b) portions should be collected and the sample sealed as described in

IOM 4.5.4.

4.1.4.1 - Definition - Official Sample An Official Sample is one taken from a lot for which Fed-eral jurisdiction can be established. If violative, the Official Sample provides a basis for administrative or legal action.

Official Samples generally, but not always, consist of a physical portion of the lot sampled. To be useful, an Offi-cial Sample must be:

1. Accompanied by records establishing Federal jurisdic-tion, and identifying the persons having knowledge of the lot's movement and custody of the records. (Evi-dence of Interstate movement is not required for medi-cal device samples, but, according to policy, is to be obtained when a seizure, injunction, prosecution or civil penalty is contemplated). See IOM 4.4.7.

2. Representative of the lot from which collected.

3. If a physical sample, large enough to permit proper laboratory examination and provide a 702(b) reserve portion when necessary.

4. Handled, identified, and sealed in such a manner as to maintain its integrity as evidence, with a clear record of its chain of custody.

4.1.4.2 - Documentary Samples In a "Documentary" (or "DOC") sample, no actual physical sample of the product is taken. Other elements of an offi-cial sample described in 4.1.4 and 4.1.4.1 are required --see special official sealing instructions below. This official sample consists of the article's labels (or label tracings, photocopies, or photos), accompanying labeling (leaflets, brochures, promotional materials, including Internet web-sites, etc.) and documentation of interstate movement (freight bills, bills of lading, affidavits, etc. See IOM 4.4.7) Photos of the product, drawings, sketches or schematics, production records, diagrams, invoices or similar items may also be part of the sample. See IOM Exhibits 4-1 and 4-2. As a rule, no FDA 484, receipt for samples is issued during collection of a DOC Sample. See subparagraph

5.2.4.1 for physical evidence exception.

A DOC sample is collected when an actual physical sample is not practical (e.g., very large, expensive, com-plex, permanently installed devices), in instances where the article is no longer available, or when there is little need for laboratory examination. A single piece of life support equipment for example, which must remain in emergency service until a replacement is available, may be sampled in this manner.

Another instance where a DOC sample might be collected involves a shipment of product recommended for seizure based on misbranding charges. During availability check, the lot sampled is found to have been distributed; how-ever, a new shipment, identically labeled, is on hand. In this instance, the new shipment may be sampled on a DOC basis since another physical sample and examina-tion is not required. Regulatory action may proceed on the basis of the earlier examination. Thus, only labeling, transportation records, the appropriate dealer affidavits, and an inventory of product on hand need be obtained.

A variation of this procedure involves collecting one or more units and removing (stripping) the original la-bels/labeling from the product container. It is frequently easier and quicker to collect relatively inexpensive units to field strip than it is to photocopy or photograph all accom-panying labels. The sample is handled in exactly the same manner as any other DOC sample, once original labeling has been removed and the remainder of the sample de-stroyed. A prominent explanation on the C/R alerts re-viewers that the original units collected were destroyed after the original labeling was removed. This procedure is not appropriate where complete, intact, labeled units are desired for exhibit purposes, even though there is no intention of analyzing the units obtained.

A documentary sample collected to document GMP de-viations, should contain copies of records obtained that document the deviations encountered. You should explain what is being documented in the remarks section of the documents obtained screen in FACTS. Fully describe any record collected as part of the DOC sample and where possible indicate the page of the document that demon-strates the deviation.

When photos are taken as part of DOC samples, the rolls of exposed film should - unless developed by the Investigator - be sent to established commercial film dealers or color processors for developing. Report the identity of the film processor on the FDA 525. Also see

IOM 5.3.4.

See IOM 4.5.2.5 for guidance on identifying records asso-ciated with a DOC sample. Do not officially seal these re-cords, but list them on the C/R. If any photos are taken as part of the DOC sample, the negatives or electronic me-dia, if any, must be officially sealed per IOM 5.3.4.2 or IOM 5.3.4.3. See IOM Exhibits 4-1 and 4-2 for examples of DOC samples. Attach the documents, photos and nega-tives along with any other records associated with the sample to the printed FACTS Collection Record. See IOM 4.4.10.5.

4.1.4.3 - In-Transit Samples

In-Transit samples are those collected from lots held on loading/receiving docks of steamships, truck lines, or other common carriers, or being transported in vehicles. The lot is considered to be in-transit if it meets any of the following characteristics:

1. A Bill of Lading (B/L) or other order to ship a lot inter-state has been issued.

2. The owner/shipper or agent acknowledges, preferably by signed affidavit, he has ordered the lot to be shipped interstate.

3. The owner or operator of the common carrier acknowledges, preferably by signed affidavit, he has an order from the shipper to move the lot interstate.

4.1.4.4 - 301(k) Samples Section 301(k) of the FD&C Act [21 U.S.C. 331 (k)] describes prohibited acts, which can result in one or more separate legal procedures. A sample collected from a lot of food, drug, device or cosmetic which became adulterated or misbranded while held for sale, whether or not the first sale, after shipment in interstate commerce is often referred to as a "301(k) Sample". The term "301(k) Sample" is misleading, but widely used within FDA to describe certain samples collected from lots which become violative after shipment in interstate commerce.

Since some act took place which resulted in the adultera-tion or misbranding of a previously nonviolative product after shipment in interstate commerce, the "301(k)" docu-mentation is incomplete without identifying the act, estab-lishing when and how it occurred, and the person(s) responsible for causing the violation. This feature, more than any other, distinguishes a "301(k) Sample" from the other Official Samples. When you report the sample col-lection, the responsible party will always be the dealer.

See IOM Exhibits 4-1 and 4-7, “301(k) affidavit.”

For example, to document insect adulteration of a finished product, caused by a live insect population in the proc-essing areas of a food manufacturer such as a bakery, you must document receipt of clean raw material and sub-sequent adulteration caused by the firm's handling or processing of the raw material. Therefore, you would need to show there was an insect infestation at the firm that ei-ther did, or may have contaminated the finished product.

You would need to collect a sample of the clean incoming flour, and subsamples at points in the system to demon-strate where insect infestations exist in the system. In situations where sampling may disturb static points in the system, which may result in a higher level of adulteration of the finished product than normal, you should sample in reverse.

301(k) samples can also be used to document adultera-tion (including noncompliance with GMPs) or misbranding of other regulated commodities, including drugs and bio-logics. If possible, when collecting a 301(k) sample cov-ering a drug product, you should attempt to document 'adulteration' or 'misbranding' of the active ingredient by the firm's actions. In the case of a biologic (for example, whole blood), which has not moved in interstate com-merce, document the interstate receipt of the bag, and the firm's subsequent 'adulteration' or 'misbranding' of the anti-coagulant (considered a drug) in the blood bag.

4.1.4.5 - Induced Sample An induced sample is an Official Sample ordered or ob-tained by agency response to some type of advertisement or promotional activity. The sample is procured by mail, telephone, or other means without disclosing any associa-tion of the requester or the transaction with FDA. See IOM

4.3.5.4 for additional information.

4.1.4.6 - Undercover Buy An "undercover buy" is an Official Sample, similar to and obtained in much the same manner as an "induced sam-ple". In an "undercover buy", however, the solicitation is made in person, usually under an alias. Pre-arranged ex-planations or cover stories are necessary to dispel any suspicions about the requester that may surface in face-to-face discussions. "Undercover buys" are frequently used in investigating complaints of illegal activity where the information cannot be substantiated or refuted through more conventional means.

4.1.4.7 - Post Seizure (P.S.) Sample A lot under seizure is in the custody of the U. S. Marshal.

If either the claimant or the government desires a sample from the seized lot, for any reason, it may be collected only by court order. In most cases, the order will specify how the sample is to be collected, and may provide for each party to collect samples. If the order was obtained by the claimant, permit the claimant's representative to de-termine how his/her sample collection is made. If the method of collection is improper, make constructive sug-gestions, but do not argue. Report exactly how the sample was drawn. Unless the claimant objects, mark subsamples collected with "P.S.", your initials and date. "P.S."

Samples are Official Samples.

Do not pay for Post Seizure Samples or any samples col-lected of a lot reconditioned under a Consent Decree. See

IOM 4.2.8.1.

4.1.4.8 - Domestic Import Sample To record information on FDA's total coverage of imported products, an additional classification of samples, "Domes-tic Import" or "DI" was devised. These are Official Sam-ples of foreign products, which have passed through customs and are in domestic commerce. The FDA may have previously taken a sample of the product while in import status, or the product may have been permitted entry without being sampled. If sampled while still in im-port status, the samples collected are import samples, and not "DI" Samples. However, once the product leaves im-port status and enters domestic commerce, any sample collected is considered an Official "Domestic Import" (DI) Sample. Note: When collecting DI Samples, especially if a violation is suspected, attempt to determine the port of entry and importer of record. Report this information on the CR. Include the name of the Country of Origin of the product and the Country Code if known.

A sample is classed as Domestic Import (DI), if any of the following situations apply:

1. The label declares the product to be from a foreign country.

2. The label bears the word, "Imported".

3. Records obtained or reviewed reveal the product origi-nated in a foreign country.

4. It is known that the product is not grown or produced in the US; it is packed as a single item with few or no other ingredients added, and it is not manipulated in any major manner, which changes the product or its composition. For example, "Olive Oil" imported in bulk and merely repacked with no added ingredients and no manipulation would be a "DI" sample, while pepper which is processed, ground and packed after entry would not. However, retail packages of ground pepper processed and packaged in a foreign country would be "DI" Samples.

5. Samples of imported raw materials, which are collected before further processing or mixed with other ingredi-ents.

DI samples are significantly different from other official samples in another important respect. Unlike domestic products, where considerable information is readily avail-able on manufacturing and distribution channels, it is fre-quently difficult to identify the responsible parties for products of foreign origin once they enter domestic com-merce. The most practical way is to establish a paper trail of records going back as far as possible in the distribution chain to the actual entry.

Identifying "DI" Samples - When identifying the physical samples, related documents and filling out the seals of Domestic Import samples, preface the sample number with the prefix "DI" in the same manner that other sample type prefixes are used (such as, "DOC", "FS" (See IOM 4.1.5), "PS", etc.)

4.1.4.9 - Import Sample Import samples are physical sample collections of prod-ucts, which originate from another country, collected while the goods are in import status. Import status ends when Customs has cleared an entry for the shipment. See IOM

4.1.6.1 and chapter 6.

4.1.4.10 - Additional Sample

This is a physical sample collected from a previously sampled lot of either a domestic or imported product.

1. Additional Import Samples - The sample collected must have the same sample number as the original sample collected.

2. Additional Domestic Sample - The sample collected may have another sample number, but it must be flagged as an "ADD" Sample and the original sample number referenced in the "Related Sample" block on the Collection Record.

4.1.4.11 – Reconditioning Sample Reconditioning Samples - These are taken from lots reconditioned under a Decree or other agreement to bring the lots into compliance with the law. The sample is taken to determine if reconditioning was satisfactorily performed.

These samples should be submitted as Official Samples.

4.1.4.12 - Audit/Certification Sample A sample collected to verify analytical results provided by a certificate of analysis or private laboratory analysis that purports to show a product complies with the FD&C Act and/or regulations. This sample type will usually be used with an import sample. See IOM 4.1.4.9.

The ORA Lab Manual, Volume 3, Section 7 provides specific guidance on FDA audit samples. FDA audit samples provide an opportunity for investigators to examine privately sampled regulated commodities for conformance with the associated submitted private lab package. Prior to collecting a FDA audit sample, careful examination of the lot should be conducted for comparison to private lab package evidence (i.e. photographs and documentation). Examples of items to note during examination and comparison of the private lab's packet include:

• Evidence of marked cartons distributed throughout the lot indicative of a representative sample.

• Marked cases that are consistent with the submitted lab package.

• Quantity removed for sampling consistent with the lab package.

• Careful attention should also be paid to any indication that the cartons selected for sampling by the private sample collector have been staged for sampling. Staging can occur through markings, deliberate damage to labeling, placement within the pallets, etc.

It is important, if evidence is found that a non-conforming private sample was collected, to immediately terminate audit activities/sampling and to report adverse findings to appropriate Compliance staff for evaluation. The Agency will then make decisions on a lot-by-lot, case-by case basis regarding the entries/sampled products submitted for importation.

Audit samples should be recorded under the same PAC codes as surveillance samples and can apply towards the completion of applicable Workplan and/or Performance goals.

4.1.4.13 - Mail Entry Sample A mail entry sample is a sample of an imported product that enters the U.S. through the U.S. Mail. See IOM 4.1.4.9.

4.1.5 - FOOD STANDARDS SAMPLE

Food Standards (FS) samples are collected to provide information on which to base Food Standards. Sample integrity is maintained in the same manner as Official Samples.

Note: Samples of standardized foods are not FS Samples.

4.1.6 - INVESTIGATIONAL SAMPLES

These samples, referred to as "INV Samples", need not be collected from lots in interstate commerce or under federal jurisdiction. They are generally collected to docu-ment observations, support regulatory actions or provide other information. They may be used as evidence in court, and they must be sealed and their integrity and chain of custody protected. Examples of INV Samples are:

1. In-Line/Factory Food Samples - Raw materials, in-process and unpackaged finished products to demonstrate manufacturing conditions. See IOM 4.3.7.7.3

2. Exhibits - Filth exhibits and other articles taken for ex-hibit purposes during inspections to demonstrate manufacturing or storage conditions, employee prac-tices, and the like. Typically filth exhibits submitted as part of an INV sample are not tied to any specific lot of product, but are meant to illustrate the conditions at a firm. An example of an INV filth sample would be ro-dent excreta pellets, apparent nesting or other rodent gnawed material, and other evidence of rodent activity collected from the perimeter and at multiple locations throughout a manufacturing facility or warehouse in or-der to document widespread rodent infestation. See

IOM 4.4.10.1.7

3. Environmental Samples – See IOM 4.3.7.7.1

4. Certain Complaint Samples - Injury and illness investigation samples from certain complaints where there is no Federal jurisdiction, or where the alleged violation offers no basis for subsequent regulatory ac-tion. Complaint samples from lots for which Federal ju-risdiction is clear should be submitted as Official Samples.

When identifying the sample/sub samples and documents related to the sample, and filling out seals, preface the sample number with "INV" in the same manner as other sample prefix types are used (e.g. "DOC", "DI").

Note: Photographs taken in a firm are not samples. They are exhibits except when they are part of a DOC Sample.

See IOM 4.5.2.4, 5.3.3, and 5.3.4.

4.1.6.1 - Non-Regulatory Sample Samples collected and analyzed by FDA for other federal, state, or local agencies of products over which the FDA has no jurisdiction.

SUBCHAPTER 4.2 - DEALER

RELATIONS

4.2.1 - DEALER DEFINITION AND GOOD

WILL

For sample collection purposes, the dealer is the person, firm (which could include the manufacturer), institution or other party, who has possession of a particular lot of goods. The dealer does not have to be a firm or company, which is in the business of buying or selling goods. The dealer might be a housewife in her home, a physician, or a public agency; these dealers obtain products to use but not to sell. The dealer may be a party who does not own the goods, but has possession of them, such as a public storage warehouse or transportation agency.

Rapport with the dealer is important to the success of your objective. All dealers, including hostile ones, should be approached in a friendly manner and treated with fairness, honesty, courtesy and consideration. A dealer may be called as a Government witness in a court case, and a favorable attitude on his/her part is to be sought. Never use strong-arm tactics or deception, but rather be profes-sional and demonstrate diplomacy, tact, and persuasion.

Do not make unreasonable demands.

Introduce yourself to the dealer by name, title and organi-zation; present your credentials for examination, and, if appropriate, issue an FDA 482, Notice of Inspection. See IOM 4.1.1.2, 4.2.4, 5.1.1.3 and 5.2.2. Explain the purpose of your visit. Be prepared to answer the dealer's questions and attempt to relieve any apprehensions while at the same time being careful not to reveal any confidential information. Do not disparage the product, its manufacturer, or shipper. Do not reveal the particular violation suspected unless the dealer is responsible, or unless you ask him/her to voluntarily hold the goods. The very fact we are collecting a sample is often reason enough to arouse the dealer's suspicions about the legality of the product.

4.2.2 - DEALER OBJECTION TO

SAMPLING PROCEDURE

If the dealer objects to your proposed sampling technique, attempt to reach a reasonable compromise on a method that will provide a satisfactory, though perhaps not ideal, sample. Assure the dealer that you will make every effort to restore the lot to its original state, that you are prepared to purchase a whole unit to avoid leaving broken cases, and that the Agency will reimburse him/her for additional labor costs incurred as a result of sampling. See IOM

4.2.8. If a reasonable compromise cannot be reached, proceed as a refusal to permit sampling.

4.2.3 - REFUSAL TO PERMIT SAMPLING

Challenges to FDA authority while collecting samples may be encountered by a dealer who, for various reasons including, personal and professional, opposes the activities of the Agency, or of governmental units in general.

Refusals to permit sample collection commonly emerge unless you can identify a section of the law which specifi-cally authorizes it. The suggested approach for dealing with these individuals is to use patient, tactful persuasion, pointing out that the sample is a part of the investigations authorized in Section 702(b) of the FD&C Act [21 U.S.C.

372(b)]. If you have not already done so, issue an FDA

482 - Notice of Inspection (except in the case of foreign inspections- see IOM 5.1.3) as soon as it becomes apparent the dealer will continue to object.

Point out and discuss the authorities provided by FD&C Act sections 702(a), 702(b), 704(a), 704(c), 704(d) [21 U.S.C. 372(a),(b), 374(a), (c), (d)] and the precedent case mentioned in IOM 2.2.1. If refusal persists, point out the criminal prohibitions of Section 301(f) of the FD&C Act [21 U.S.C. 331(f)].

If samples are still refused, leave the premises and con-tact your supervisor immediately. Refer to IOM section

5.2.5 and Compliance Policy Guide manual section

130.100 for further discussions on resolving the impasse.

4.2.3.1 - Limiting or Preventing Collection of Samples of a Drug

Preventing an authorized representative of the FDA from collecting drug samples may be considered as limiting the inspection. If you have appropriately issued a FDA 482 – Notice of Inspection and the dealer impedes your ability to collect samples, point out and discuss the authority provided by Section 501(j) of the FD&C Act [21 U.S.C.

351(j)] under Section 707 of the Food and Drug Administration Safety and Innovation Act (FDASIA), that potentially deems all drugs manufactured at the facility adulterated in the case of limiting an inspection. In situations where you have begun an inspection but no FDA 482 is issued (e.g., foreign inspections), document this fact and the limiting activities in your notes based on the authority described above.

If refusal persists, point out that adulteration under section 501(j) of the FD&C Act [21 U.S.C. 351(j)] could lead to further prohibited acts under 301(a), (b), and (c) [21 U.S.C. 331(a), (b), (c)]).

Also see IOM 2.2.1.4.

4.2.4 - NOTICE OF INSPECTION

See IOM 4.1.1.2, 5.1.1.3, 5.1.1.5 and 5.2.2.

Each time you issue an FDA 482, Notice of Inspection, and subsequently collect a sample, issue the appropriate sample receipt (FDA 472 - Carriers Receipt for Samples or FDA 484 -Receipt for Samples).

4.2.4.1 - Dealer Responsible for Condition of Lot An FDA 482 should be issued before collecting samples from firms, carriers, or individuals whom FDA can take regulatory action against for the violative condition of the lot. See IOM 4.1.1.1. When in doubt, issue a Notice of In-spection. If there is no EIR, attach a copy of the FDA 482 to the printed FACTS Collection Record. See IOM 4.4.10.5.

4.2.4.2 - Refusals See IOM 4.2.3. If a FDA 482 has been issued prior to a sample refusal situation, the copy of the FDA 482 is to accompany the EIR or a memorandum outlining the facts of the refusal if no EIR is prepared.

If you are on a foreign inspection in which a FDA 482 is not issued, reference relevant Compliance Programs and Chapter 3 of the Guide to International Inspections and Travel Manual for reporting guidance.

4.2.4.3 - Carrier In-Transit Sampling Caution: See IOM 4.3.4 for conditions, which must be met before collecting in-transit samples from common carriers.

When collecting samples from in-transit lots in possession of a commercial carrier, issue the carrier or his agent an FDA 482. Attach a copy to the printed copy of the FACTS Collection Record. See IOM 4.4.10.5.

4.2.4.4 - Dealer Requests Notice of Inspection When inspecting a dealer, and an FDA 482 does not need to be issued, but the dealer requests a Notice of Inspec-tion, issue an FDA 482. Attach a copy to the printed FACTS Collection Record. See IOM 4.4.10.5.

4.2.5 - RECEIPT FOR SAMPLES

Any time you collect a sample after issuing an FDA 482, Notice of Inspection, always issue the appropriate sample receipt FDA 472 - Carriers Receipt for Samples or FDA 484 Receipt for Samples.

Always issue an FDA 484 as a receipt for samples of pre-scription drugs, including narcotics and controlled sub-stances. See IOM 4.2.5.3, 4.2.5.4, and 5.2.4.

4.2.5.1 - Carriers/In-Transit Lots Caution: See IOM Exhibit 4-4. Give the original to the car-rier or his agent and route a copy to the appropriate fiscal unit for your district. The fiscal clerk will notify the con-signee and consignor that a sample has been collected so the owner can, if desired, bill FDA for the sample.

4.2.5.2 - Dealer Requests Receipt When collecting physical samples of regulated products, not in connection with an EI or where no FDA 482 has been issued, do not routinely issue an FDA 484, Receipt for Samples, except for prescription drugs, narcotics, or controlled substances. See IOM 4.2.5.3 and 4.2.5.4. If any dealer specifically asks for a receipt, prepare and issue an FDA 484 and route a copy with any other records associ-ated with the collection record. See IOM 4.4.10.5.

4.2.5.3 - Narcotic and Controlled Rx Drugs Regulations of the Drug Enforcement Administration (DEA) impose strict controls and comprehensive record-keeping requirements on persons handling narcotics and controlled substances. As a result, an FDA 484 must be issued for all samples of such drugs collected by FDA.

Each dealer in narcotic and controlled drugs is assigned its own unique DEA registration number. Any time you collect a sample of a narcotic or controlled drug, be sure the Dealer's DEA Registration Number is entered in the appropriate block of the FDA 484. Double-check the num-ber for accuracy. An error may result in possible investi-gation for drug shortages.

When samples of narcotic or controlled drugs are collected, the complete DEA Registration Number must be entered on the - RECEIPT FOR SAMPLES, given to the person from whom the samples were collected.

Concise completion of the FDA 484 for samples of narcotic or controlled drugs includes the trade and chemical name, strength, sample size, container size, lot, batch, or control number, manufacturer's name and address, district address and the sample number. See IOM 4.4.10.5. Use of the FDA 484 as a Receipt for Samples of these drugs has the approval of DEA. (See reverse of FDA 484).

4.2.5.4 - Prescription Drugs (Non- Controlled) Issue an FDA 484, Receipt for Samples, when samples of prescription legend drugs are collected from dealers, indi-viduals, or during inspections. Attach a copy of the FDA 484 to the printed FACTS Collection Record. See IOM 4.4.10.5.

4.2.5.5 - Preparation of FDA 484 Complete the blocks on the FDA 484 (Exhibit 4-5), Re-ceipt for Samples, as follows:

Block 1 - Enter your District address and telephone num-ber including area code.

Block 2 - Enter the complete name and official title of the individual to whom you issue the FDA 484.

Block 3 - Enter date on which you finished collecting the sample. If you spent more than one day on the sample collection, enter the date you completed sampling.

Block 4 - Enter complete Sample Number here. Be sure to include any prefixes such as "DI", "INV", etc.

Block 5 - Enter firm's legal name.

Block 6 - If the firm is a dealer in narcotics or control drugs, enter their DEA Number here.

Block 7 and 8 - Enter number, street, city, state, and zip code of firm.

Block 9 - Enter a brief description of the article collected, including the number and size of units collected, product name and any identifying brand and code marks.

Block 10 -. Check the appropriate box on the FDA 484.

Block 11 - Enter the amount paid for the sample (even if borrowed, the owner may ask rent for it) and check the appropriate box. If there is no charge (always offer pay-ment except for Post Seizure Samples), enter N/C and leave boxes blank. If, as a last resort, it is necessary for you to use your personal check or credit card and this is acceptable to the person, enter amount and check "Credit Card." box.

NOTE: Older editions of the FDA 484 do not have a "Credit Card." box. If using older editions,, write "Credit Card" following the sample amount.

Block 12 - In instances where payment is made for the Sample, whether actually purchased, borrowed or pro-vided at no charge, and there is no Dealer's Affidavit or any other document executed to show the owner's signa-ture for receipt of payment, obtain the signature of the person receiving payment for the sample.

If Dealer's Affidavit, regular Affidavit or other document is used, the recipient's signature will be on that document so it is not necessary for him to also sign the FDA 484. In this case insert an applicable statement such as "Dealers Affi-davit signed" in this block.

Blocks 13, 14, and 15 - Enter your name, title and sig-nature.

4.2.5.6 - Routing of FDA 484 Original - Give the signed original to the firm, preferably to the individual to whom you gave the FDA 482 and FDA

483. See IOM 4.2.5.3 regarding receipts for narcotics and controlled drug samples.

First Carbon - Accompanies the EIR. If no EIR is involved such as when collecting a sample and the dealer specifi-cally requests a receipt, attach it to the original Collection Record. See IOM 4.2.5.2, 4.2.5.3, and 4.2.5.4.

Second Carbon - This is an extra copy for use as needed.

If not filed in the factory file, or attached to the C/R or not otherwise needed, it may be destroyed.

If exact copies are used instead of carbon copies, then route one exact copy with the EIR and a second as above.

When numerous subsamples are collected, the second carbon or exact copy may be attached to the original C/R to avoid repetition of the sub descriptions. When used for this purpose, be sure the numbers you assign to the physical subsamples matches those on the FDA 484, and that the subs are adequately described. See IOM Exhibit 4-5. If errors are noted after issuance, handle the same way as instructed under IOM 5.2.3.1.6.1 and IOM 5.2.3.1.6.2.

4.2.6 - DEALER IDENTIFICATION OF LOT

AND RECORDS

Positive identification of sampled lots and the records covering their sales and shipment are essential to legal proceedings. The dealer's identification of a sampled lot and his identification of the records covering I.S. shipment should be factual and specific. If there is a question about accurate identification of the lot or records, determine all facts and establish identification as clearly as possible. Be alert to any identifying marks, which may later be used on the witness stand for positive identification.

4.2.6.1 - Private Individuals When collecting Official Samples from private individuals, ask the individual to initial and date the label, wrappings, promotional literature, etc. This will aid in positively identi-fying the product and related documents in any court proceedings that may develop months, or even years later.

4.2.6.2 - Seriously Ill Individuals If you collect samples from a person for contemplated regulatory action, and it is obvious the person is seriously ill, you should attempt to locate and obtain a corroborating statement and identification from someone else. This cor-roborating witness should have personal knowledge of the facts and be available if the principle witness cannot testify in a legal proceeding.

4.2.7 - SAMPLING FROM GOVERNMENT

AGENCIES

See IOM Subchapter 3.2 for sampling information specific to Other Government Agencies (OGA).

4.2.8 - PAYMENT FOR SAMPLES

Payment for all samples, except those collected under authority of a Court Order or Decree, shall be offered to the person from whom the sample(s) were obtained regardless of the amount. See IOM 4.2.8.2.

An exception is import samples. FDA does not pay for Im-port samples at the time of collection.